KR101467731B1 - Composition for preventing hair loss or promoting hair growth comprising extract of Miscanthus sinensis var. purpurascens - Google Patents

Abstract

The present invention relates to a pharmaceutical composition containing a Miscanthus sinensis var. purpurascens extract, as an active ingredient, for preventing hair loss or promoting hair growth. More particularly, the present invention provides a cosmetic composition or a health food composition containing a Miscanthus sinensis var. purpurascens extract, as an active ingredient, for exhibiting an effect of preventing hair loss or promoting hair growth. The Miscanthus sinensis var. purpurascens extract reduces an expression level of TGF-β1, which is increased by an influence of stress, in a C57BL/6 female mouse in which chronic stress is induced, so that a beneficial effect on hair growth is demonstrated. Also, the Miscanthus sinensis var. purpurascens extract exhibits an excellent effect on hair loss and hair growth by in vivo test.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing hair loss or promoting hair growth, which comprises a crude flower extract as an active ingredient. purpurascens}

The present invention relates to a composition for preventing hair loss or for promoting hair growth, which comprises an extract of a flower of the genus Aspergillus as an active ingredient.

Recent rapid economic growth and improvement of living standards have improved the quality of life of the people, but due to pollution and environmental pollution, modern people are exposed to external stimuli and diseases. In particular, it has been found that alopecia is caused by local infection, genetic predisposition, and endocrine disorders related to hair, but recent studies have shown that various factors related to hair loss such as stress, adverse effects due to environmental pollution, . In the mechanism of hair loss, immune cells and neutrophils are activated by the environment such as stress, causing an inflammatory reaction, destroying hair follicle tissue, causing hair cell death, and causing hair loss.

Hair loss is not limited to men but is increasing in women as well, and teenagers are increasingly worried about hair loss. The domestic hair loss population has increased from about 5 million in 2006 to 8 million in 2007 and reached about 9 million in 2008 and increased by 200% in 2006 to over 10 million by the end of 2011. From 2001 to 2008, the proportion of female hair loss patients increased by 73%, male hair loss patients increased by 49%, and the rate of hair loss disease among young people in their 20s and 30s increased significantly (National Health Insurance Corporation, February ; 2012).

Currently, there are two types of minoxidil and finasteride approved by the FDA as a hair growth promoting agent. Minoxidil has been used as an oral antihypertensive drug, but it has been observed that hirsutism appears in patients taking this drug, and is currently used for alopecia areata for scalp application. Minoxidil is a pyrimidine derivative that is widely used as a treatment for hair loss because it enlarges the blood vessels of the scalp, locally increases blood flow, activates the hair cells, slows the progress of hair loss, and has the effect of growing fluff. However, according to several clinical studies, minoxidil has been reported to be effective only in less than 50% of patients, and it is effective in alopecia, but when it is discontinued, hair loss again occurs. Finasteride is the first oral therapeutic for the treatment of male androgenetic alopecia that prevents hair loss by inhibiting type Ⅱ 5α-reductase and thereby promotes hair growth. Approximately 2.6 million people around the world are currently using this drug after approval by the FDA in 1997 .

However, minoxidil has been associated with weight gain, edema, increased heart rate, angina pectoris, dermatitis, itching, and side effects of such a hair growth promoting agent. Finastelide is reported to be a serious example of adverse effects such as male sexual dysfunction and birth defects. There is a problem that is limited or the patients themselves show resistance to drugs. As a result, consumers are interested in hair loss preventive substances derived from natural materials, and various studies on plant extracts are being conducted.

Miscanthus sinensis var. Purpurascens is a perennial plant that grows throughout the Korean peninsula and is 1-2 m high. The stem is cylindrical and slightly thick. Leaves are 40 ~ 70cm in length, 1 ~ 2cm long, and the ends are gradually pointed. The middle vein is coarse and white, and the base is a long leaf sheath and has long hairs. At the end of autumn, a small ears hang tightly, forming a flower body at the end of the stem.

Korean Laid-Open Patent No. 2013-0027338 (published on March 15, 2013)

An object of the present invention is to provide a pharmaceutical composition, a cosmetic composition or a health food composition for preventing hair loss or promoting hair growth, which comprises an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

The present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth, which comprises an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

In addition, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

Also, the present invention provides a health food composition for preventing hair loss or promoting hair growth, comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

The present invention relates to a composition for preventing hair loss or promoting hair growth comprising an extract of T. japonica as an active ingredient and a method for inhibiting hair loss in a C57BL / 6 female mouse in which stress is induced by stress, And it was analyzed that it has a good effect on hair growth by decreasing expression amount. In vivo (in vivo test was conducted to find that there was an excellent effect on hair loss or hair growth. Therefore, it is considered that the herb flower extract is highly applicable as a hair and hair loss treatment agent.

FIG. 1 is a photograph of a hair growth test result of C57BL / 6 mouse for each treatment group. The hair of the back skin of the mouse was epilated, and DMSO, minoxidil and MSP extract were applied for 3 weeks. NC; DMSO treated group (negative control group), NCS; DMSO + stress-treated group, PC; 3% minoxidil (positive control) treated group, PCS; Minoxidil + stress-treated group, MSP; The herb flower extract treatment group, MSPS; The herb flower extract + stress treatment group.
Figure 2 shows the result of substance P expression for each treatment group. This is a representative histological observation comparing the immunohistochemical staining of substance P antigen in the hair loss model of C57BL / 6 mice to which the subject compound was applied for 3 weeks. NC; DMSO treated group (negative control group), NCS; DMSO + stress-treated group, PC; 3% minoxidil (positive control) treated group, PCS; Minoxidil + stress-treated group, MSP; The herb flower extract treatment group, MSPS; The herb flower extract + stress treatment group.
Figure 3 shows the results of stem cell factor (SCF) expression for each treatment group. This is a representative histological observation comparing the immunohistochemical staining of SCF antigen in the hair loss model of C57BL / 6 mice to which the subject compound was applied for 3 weeks. NC; DMSO treated group (negative control group), NCS; DMSO + stress-treated group, PC; 3% minoxidil (positive control) treated group, PCS; Minoxidil + stress-treated group, MSP; The herb flower extract treatment group, MSPS; The herb flower extract + stress treatment group.
Figure 4 shows the relative expression of TGF-? 1 and VEGF in each treatment group. The relative expression of TGF-β1 and VEGF was analyzed by real-time PCR. NC; DMSO treated group (negative control group), NCS; DMSO + stress-treated group, PC; 3% minoxidil (positive control) treated group, PCS; Minoxidil + stress-treated group, MSP; Dried herbaceous flower extracts (dissolved in DMSO), MSPS; The herb flower extract + stress treatment group. Values sharing the same superscript letters differ significantly at p <0.05 by Duncan's multiple range test.

The present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth, which comprises an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

Specifically, the herb flower extract is preferably extracted with any one solvent selected from the group consisting of water, C1 to C4 lower alcohols, dimethyl sulfoxide (DMSO), and a mixed solvent thereof. It is not.

Specifically, the composition comprises 0.1 to 50 parts by weight of the herbal flower extract per 100 parts by weight of the composition.

Specifically, the hair loss may be hair loss caused by stress, but the present invention is not limited thereto.

When the composition of the present invention is a pharmaceutical composition, the pharmaceutical composition may be formulated into a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment, a pasta agent and a cataplasma agent. In addition, the pharmaceutical composition may contain a pharmaceutically acceptable carrier in addition to the herbal flower extract. Such a pharmaceutically acceptable carrier is commonly used in pharmaceutical preparations, and includes lactose, dextrose, sucrose, But are not limited to, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, Tartrate, magnesium stearate, mineral oil, and the like, but is not limited thereto. In addition, the pharmaceutical composition may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. as an additive.

The pharmaceutical composition may be administered according to the severity of depilation, and local administration is usually preferred. The dosage of the active ingredient in the pharmaceutical composition may vary depending on the route of administration, the severity of the disease, the age, sex, and weight of the patient, and may be administered once to several times per day.

In addition, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

When the composition of the present invention is a cosmetic composition, the cosmetic composition may contain a conventional assistant such as a stabilizer, a solubilizing agent, a vitamin, a pigment and a fragrance, and a carrier in addition to an effective ingredient extract of the herb extract.

The formulations of the cosmetic composition may be prepared in any form conventionally produced in the art, and examples thereof include hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, Hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair drying agent, hair preservative, hair dye, hair wave, hair cosmetic cream, hair moisturizing cream, But are not limited to, hair removers, hair bleaches, hair gels, hair glazes, hair dressers, hair lacquers, hair moisturizers, hair mousses and hair sprays.

When the formulation is a paste, cream or gel, an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component .

When the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Or propellants such as dimethyl ether.

When the formulation is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, - butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, a microcrystalline cellulose , Aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

Also, the present invention provides a health food composition for preventing hair loss or promoting hair growth, comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

The health food composition may be provided in the form of powder, granules, tablets, capsules, syrups or beverages. The health food composition may be used in combination with other food or food additives other than the herb extract according to the present invention, Can be suitably used according to the method of The amount of the active ingredient to be mixed can be suitably determined according to its use purpose, for example, prevention, health or therapeutic treatment.

The effective dose of the herbal flower extract contained in the health food composition may be used in accordance with the effective dose of the pharmaceutical composition. However, for the purpose of health and hygiene or for long-term intake for health control purposes, And it is clear that the active ingredient can be used in an amount exceeding the above range since there is no problem in terms of safety.

There is no particular limitation on the type of the health food, and examples thereof include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, Drinks, alcoholic beverages and vitamin complexes.

On the other hand, the herbal flower extract used in the composition of the present invention is a natural product with little toxicity and side effects, so that it can be safely used for prolonged administration even for prophylactic purposes.

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention, but the scope of the present invention is not limited to the following examples. Embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.

< Experimental Example >

The following experimental examples are intended to provide experimental examples that are commonly applied to the respective embodiments according to the present invention.

1. Experimental animal treatment

Six-week-old female C57BL / 6 mice were randomly divided into 6 groups (NC group: DMSO treated group, NCS: DMSO + stressed group, PC group: minoxidil treated group, PCS group: Minoxidil + stress treatment group, MSP: itch flower extract treatment group, MSPS: itch flower extract + stress treatment group), and the extract was dorsally applied to the dorsal skin for 3 weeks.

The experimental animals were housed four cages per cage. The environment of the cage was adjusted to room temperature 22 ± 1 ℃, relative humidity 65 ± 5%, and day and night cycle 12 hours. Diet was allowed to eat freely. Experimental animals were treated with litter, cage 45 ° tilt, negative and dietary control, and cage replacement.

On the other hand, all animal experiments in the present invention were conducted under approval of Chung Ang University Animal Experimental Ethics Committee (Approval No. 13-0035).

2. Sample preparation and application

20 mg of methanol extract (99.9%) was purchased from Korean plant extract bank and 1 mL of DMSO (Samchun Chemical, Pyeongtaek, Korea) was added for 24 hours at 37 ℃. , Washington, NY, USA). The filtered sample was diluted to a concentration of 1,000 ppm, blocked with light, and stored in a refrigerator.

One week before the start of the experiment, the hair was removed from the hair of the C57BL / 6 mouse using an electric epilator (HASUNG ELECTRONIC, NEW HASUNG PET CLIPPER POWERMAX 202, Seoul, Korea). The sample was sampled once a day, seven times a week, every 200 μl Were applied percutaneously using a pipette for 4 weeks. 3% minoxidil (Hyundai Pharm, Seoul, Korea) was used as a positive control and DMSO was used as a control group.

3. Experimental animal sacrifice

After 4 weeks of treatment, the cervical disc was removed and blood was collected from the eyeball. The organs (heart, kidney, liver, brain, spleen) and back tissue were collected and frozen.

4. Analysis of animal tissues related to hair growth

(1) Morphological observation of hair follicles: Hematoxylin and Eosin (H & E) staining

The extracted animal tissues were fixed with formalin and dehydrated with alcohol, alcohol and xylene, and embedded in paraffin.

3 μm tissue sections were stained with hematoxylin and Eosin (H & E) (Sigma Aldrich Co., St. Louis, Mo., USA) and examined using a 100 magnification optical microscope (Leica DM 500, Leica Micro-systems, Wetzlar , Germany). The thickness of the dermis and the depth of the hair follicle were measured using a microscope program scale bar.

(2) Mast cell count: Toluidine blue staining

Tissue sections were prepared in the same manner as the H & E staining method. After dehydration with alcohol and xylene according to the usual treatment steps, toluidine blue (Sigma Aldrich Co., St. Louis, MO , USA) for 2 minutes, and the number of mast cells and subcutaneous mast cells stained in purple were counted by a 200 magnification optical microscope (Leica DM 500, Leica Micro-systems, Wetzlar, Germany).

(3) Substance P: Immunohistochemical staining

(Sigma Aldrich Co., St. Louis, Mo., USA) diluted 1:50 with PBTS (PBS with 0.1% Tween 20) was dropped on the tissue section and incubated at room temperature For 12 hours and then washed. Afterwards, secondary antibody goat anti-rabbit immunoglobulin G horseradish peroxidase (IgG HRP) was dispensed into the tissues and washed in PBTS.

Each tissue was reacted with a solution of 3-3 'diaminobenzidine (Roche Diagnostics GmbH, Mannheim, Germany) in PBS at 0.1 M, and hematoxylin (Sigma Aldrich Co., St. Louis, MO, USA). After transparency, they were enclosed and observed Substance P expressed in hair follicles, mast cells and dermis by optical microscope.

(4) Stem cell factor (SCF): Immunohistochemical staining

PBT and anti-SCF antibody produced in rabbit (Sigma Aldrich Co., St. Louis, Mo., USA) diluted 1:50 were added to tissue sections and reacted for 12 hours at room temperature. After coarse, the secondary antibody (goat anti-rabbit IgG HRP) was dispensed into the tissues and washed with PBTS.

Each tissue was reacted with a solution of 3-3 'diaminobenzidine (Roche Diagnostics GmbH, Mannheim, Germany) dissolved in 0.1 M PBS, and hematoxylin (Sigma Aldrich Co., St. Louis, MO , USA), and after transparency, they were sealed and observed with an optical microscope for the degree of staining in hair follicles, mast cells and dermis.

5. Hair growth related cytokine  analysis: Real - time 중합체 chain reaction

(1) RNA extraction and cDNA synthesis

After the breeding period, the back tissue of C57BL / 6 mice was harvested and RNA was extracted using trizol. Add 500 μl of trizol to 500 μl of the disrupted crushed protein solution, and remove the protein. Voltexing, mix well, stabilize for 5 minutes, add 300 μl of chlorofrom, and let it vortex for 5 minutes at room temperature. After the centrifugation, the supernatant containing the RNA is separated, and is coagulated with isopropanol, followed by drying.

cDNA synthesis was performed using Ambion's RNase inhibitor, Mulv Res Transcriptase, and Random Hexamers (50 μM).

(2) Real-time PCR

Real-time PCR was performed using a PicoReal 96 Real-Time PCR System (TCR0096, Thermo Scientific, USA). Target gene primers were purchased from Bioneer, Inc. at a concentration of 100 pM. Prior to conventional PCR analysis for real-time PCR analysis, PCR was performed by electrophoresis at each temperature After analysis of the product band, real-time PCR analysis was performed at the most suitable temperature. Primer Sequence is shown in Table 1.

Target gene order product  size ( bp ) TGF -β1 Forward ATG GCA GCG ACC ATA CTC CTC TTT 121 Reverse AAA GAC AGC CAC TCA GGC GTA TCA VEGF Forward TGC TTA TAG GCT GTT GTG GGC TCT 187 Reverse ACA CAC CTT GAC TCT TCA CCT GCT GAPDH Forward TGT GAT GGG TGT GAA CCA CG 129 Reverse GAG CCC TTC CAC AAT GCC AA

The fluorescence reagents used in the sample analysis were Maxima SYBR green qPCR master mix (Thermo Scientific, USA) and real-time PCR analysis conditions are shown in Table 2.

PCR recipe: Dissolve 10 μl of the master mix, 1.0 μl of forward primer (12.5 pM), 1.0 μl of reverse primer (12.5 pM), 2 μl of sample and 6 μl of DEPC DW into 96 well plates for real- The volume of cytokine expression was analyzed by real-time PCR running so that the total volume was 20 μl.

Number of cycle Temperature (℃) time One 95 10 min
40 95 15 sec 60 30 sec 72 30 sec

< Example >

1. Hair growth effect

As shown in Fig. 1, on the seventh day of experiment, the back skin of the test animal changed from red to black, and the hair follicle was found to be in a growing state. On the 14th day of experiment, compared with the control group (NC), the stressed plant extracts (MSPS group) showed a larger hatching area, and the hatching growth effect was similar to that of the unstressed positive control (PC). On the 21st day of experiment, hair growth began to be covered with hair by hair growth, and hair growth was remarkable in flower extract treatment group.

2. Follicular length

As shown in Table 3, the hair follicle length of the test group treated with the extract of MSP extract was 540.5 μm in the stress-untreated group and 470.7 μm in the stress-treated group. The hair follicles of the positive and negative control groups and the hair follicles of the non- Which is significantly longer than the length. The hair follicle length of the stressed group (MSPS group) treated with herbaceous flower extract was 470.7 μm, which was significantly longer than that of the stressed group of the positive and negative control groups. The hair follicle length was shorter when the hair follicle was transferred from the growing stage to the resting stage, and the length of the hair follicle was significantly longer in the MSP extract treatment group than that of the hair follicle. . Among the MSP extract-treated group, the hair follicle length of the MSPS group was 470.7 μm, which was shorter than that of the MSP group (540.5 μm), but the difference was not significant.

3. Mast cell ( Mast cell ) Coefficient

As shown in Table 3, the number of mast cells in the experimental group treated with the extract of MSP extract was 2.67, which was significantly lower than that of the negative control group (9.38) and the positive control group (minoxidil) Respectively. The number of mast cells in the MSP extract - treated group was 7.38 and there was no significant difference with the positive control group, but the negative control group had a significant difference of 16.63. This suggests that MSP extract plays a role in blocking the secretion of inflammation-inducing substances trapped in the granules of mast cells or reducing its efficiency. MSP treatment group was significantly lower when compared with the number of mast cells in the stress untreated group and the number of mast cells in the stress treated group.

Group Follicular length (μm) Mast cell number NC 316.8 ± 28.01 ^a 9.38 ± 2.50 ^b NCS 321.4 ± 21.36 ^a 16.63 ± 3.81 ^a PC 381.6 ± 13.53 ^ab 9.25 + - 3.37 ^b PCS 345.9 ± 22.69 ^a 10.13 ± 2.80 ^b MSP 540.5 + - 38.40 ^c 2.67 ± 1.75 ^c MSPS 470.7 ± 54.10 ^bc 7.38 ± 2.20 ^b

^{Values are expressed as mean ± SE ab} Values in the same column not sharing a common superscript are significantly different at p <0.05 by Duncan's multiple range test.

4. Substance  P

Immunohistochemistry staining intensity of substance P was different according to treatment substance and stress induction. In the whole experimental group, there was no consistent trend depending on the stress incidence. However, the immune response of substance P was stronger in stressed NCS group and MSPS group. In the positive control group, substance P (Fig. 2).

5. Stem cell factor ( Stem cell factor ; SCF )

In the control group, the degree of staining was small and the epidermis was stained, but the hair follicles were stained with background staining. Immunostaining in the experimental group was stained stronger than that of the control group and the expression of SCF was high, (Fig. 3).

MSF extract showed strong immunoreactivity in SCF treated with MSP extract, suggesting that MSP extract promotes hair growth and promotes hair growth. SCF is a substance that maintains stem cells. The more SCF is expressed, the better the ability to regenerate hair follicles, and the more hair growth cytokines are expressed, thereby promoting hair growth. As a result of the experiment of the present invention, the immune response of SCF was strongly occurred in the group treated with the extract of MSP extract, and this result suggests that the treatment with the MSP extract has a positive effect on the hair growth .

6. Hair growth-related cytokines ( cytokine ) Expression

(1) TGF-β1

As shown in Table 4 and FIG. 4, the expression level of TGF-β1 was higher in the overall stressed treatment group. The expression level of TGF-β was 3.4 times higher than that of NC group in NCS group (p <0.05). In the MSP group, the expression level of TGF-β1 was lower in the MSP group than in the NC group. In the MSPS group, the expression level of TGF-β1 was significantly higher than that of the NC group, (P < 0.05). In the PC and PCS groups, the expression of TGF-β1 was significantly higher than that of the NCS group and there was no significant difference between the two groups. In MSP-treated group, the expression level of TGF-β1 was lower in NC group than in non-stressed MSP group and the expression level of TGF-β1 in MSPS group was also significantly lower than that of NCS group. These results suggest that the treatment of MSP has a positive effect on hair growth by decreasing the expression level of TGF-β1 which is increased by the influence of stress.

(2) VEGF

As shown in Table 4 and Fig. 4, the expression level of VEGF was the highest in the PC group (p < 0.05). On the other hand, the expression level of VEGF in PCS was 0.77 and the level of NCS (0.72) was not significant. As a result of VEGF analysis, the expression of VEGF, which is a hair growth promoter, was not observed when treated with MSP, but the expression of VEGF was significantly decreased in the stressed group. These results indicate that MSP does not affect the expression level of VEGF.

Group NC NCS PC PCS MSP MSPS TGF -β1 1.00 ± 0.00 ^a 3.40 0.15 ^b 2.00 ± 0.10 ^c 2.36 + 0.08 ^c 0.84 0.08 ^a 2.03 ± 0.25 ^a VEGF 1.00 ± 0.00 ^a 0.72 + 0.02 ^b 1.30 0.06 ^c 0.77 + 0.03 ^b 1.01 0.03 ^d 0.58 + - 0.03 ^b

The relative expression of TGF-β1 and VEGF was analyzed by real-time PCR. NC; DMSO treated group (negative control group), NCS; DMSO + stress-treated group, PC; 3% minoxidil (positive control) treated group, PCS; Minoxidil + stress-treated group, MSP; Dried herbaceous flower extracts (dissolved in DMSO), MSPS; The herb flower extract + stress treatment group. Values sharing the same superscript letters differ significantly at p <0.05 by Duncan's multiple range test.

Claims (6)

A pharmaceutical composition for preventing hair loss or promoting hair growth, comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient. [3] The method according to claim 1, wherein the herb flower extract is extracted with any one solvent selected from the group consisting of water, C1 to C4 lower alcohols, dimethyl sulfoxide (DMSO) Or promoting hair growth. [Claim 3] The pharmaceutical composition according to claim 1, wherein the composition comprises 0.1 to 50% by weight of a flower extract. 4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the hair loss is hair loss caused by stress. A cosmetic composition for preventing hair loss or promoting hair growth, comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient. A health food composition for preventing hair loss or promoting hair growth, comprising an extract of Miscanthus sinensis var. Purpurascens as an active ingredient.

Images